Completed PHASE3 INTERVENTIONAL 2-arm NCT00547651

AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy

AMR PH GL 2007 CL001 Phase 3 A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of First-Line Chemotherapy

Sponsor: Celgene

Conditions Small Cell Lung Cancer

Interventions Amrubicin Topotecan

Updated 2 times since 2024 Last updated: Oct 30, 2019 Started: Sep 1, 2007 Primary completion: May 1, 2011 Completion: May 1, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by Celgene and has accumulated 2 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarau, Switzerland , Amarillo, United States , Amsterdam, Netherlands , Augusta, United States , Aurora, United States , Bad Berka, Germany , Baltimore, United States , Barcelona, Spain , Bedford Park, Australia , Berlin, Germany and 124 more locations